Wockhardt Pharma News
How Wockhardt is packing for the road less travelled
Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for weight loss and anti-diabetic medicine, as it pivots away from the US generics market.
7 min read3 Apr 2025Wockhardt shares jump 4% despite the stock market crash after an update on antibiotic Zaynich. Check details
Wockhardt's share price rose 4 per cent in intraday trade on the BSE on January 13, despite weak market sentiment, after announcing over 97 per cent efficacy of its antibiotic Zaynich against resistant infections. The stock has surged nearly 210 per cent in the past year.
2 min read13 Jan 2025Popular Topics
Budget
The Union Budget contains details about the estimated receipts and the expenditure of the government for a particular fiscal year. The Budget is allotted for the upcoming fiscal year, which runs from 1st April to 31st March of the next year. Here is a quick guide on how the Union Budget is prepared
The Gensol-BluSmart saga
On 24 February, Mint first reported, citing people familiar with the developments, that Blu-Smart Mobility, Anmol Jaggi’s privately-owned electric cab-hailing service, had defaulted on Rs 30 crore worth of bonds in early February because of a cash crunch. The company subsequently paid non-convertible debenture (NCD) holders. (Even before this development, another Mint story on 4 February had spotlighted Gensol's shareholding pattern: In September 2022, Hari Shankar Tibrewala had invested in the company, part of whose stake was taken into possession by the Government of India in late 2024.) Just 10 days after we wrote about the news of Blu-Smart facing a cash crunch, things turned worse for Gensol when Care Ratings downgraded the company to default. The rating agency's action marked the start of a downward spiral for the company, which then saw its share prices crash, leading to the invocation of promoter shares and raising questions on corporate governance. Finally, on 15 April, the market regulator, the Securities and Exchange Board of India, in an interim order, minced no words when it barred the Jaggi brothers from being at the helm and ordered Gensol to undertake a forensic audit on money siphoning. Here’s a list of all these stories by Mint to understand how the company, once the poster boy of renewable energy and EV space, unravelled.